KHN column: The Roadmap lives

NewsGuard 100/100 Score
In his latest Kaiser Health News column, James Capretta writes: "Last year, Rep. Paul Ryan's 'Roadmap' -- his far-reaching plan to restore long-term budget balance through tax and entitlement reform -- was the subject of relentless attacks by those favoring a larger government role in American life. New York Times columnist Paul Krugman called Ryan the 'Flimflam Man' in a widely cited opinion piece in which he tried to dismiss the Roadmap as not a credible solution to the nation's budget problems. The congressional Democratic leadership followed up with an organized campaign aimed at demonizing the plan as a callous assault on Social Security and Medicare beneficiaries. … None of it worked. In fact, not only did the Roadmap survive the 2010 mid-term campaign, the election results -- and the dominoes that have fallen since -- have made it far safer politically for Roadmap proponents to advance the plan's ideas in the public square" (11/22). Read the entire column.


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.